IMVT

Immunovant
IMVT

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
$2.45B
EV
$2.08B
Shares Outstanding
172.13M
Beta
0.81

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$45.15
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Immunovant, Inc.

gainify
IMVT

Immunovant, Inc.

IMVT

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor fo...

Sector

Healthcare

Industry

Biotechnology

CEO

Salzmann, Peter

Employees

207

IPO Date

2019-06-21

Headquarters

320 West 37th Street, 6th Floor, New York, New York, 10018, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved